ArticleOncoTargets and therapy2020

FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer.

Yihong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.